Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiglitazar Sodium Combined With Venetoclax and Azacitidine for R/R AML
NCT06737523Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of chiglitazar in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Complete Remission Rate up to 36 months, Complete Remission with Incomplete Count Recovery up to 36 months and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
chiglitazar
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06737523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06737523.